, Taiwan
/Arafat Tarif from Pexels

Allianz Taiwan's strong capitalization boosts resilience: Moody’s

The insurer faces challenges due to its moderate overall market presence.

Allianz Taiwan’s underwriting profitability is improving albeit at a moderate pace versus its peers, which is attributed to the low product margin of its key single-premium investment-linked products, Moody's Investors Service said in a note.

Despite this, Moody’s projects its underwriting gains to maintain improvement as it widens its scale paired with a commendable product mix shift. 

“Specifically, the insurer has successfully incorporated protection riders to its investment-linked products,” the agency said.

ALSO READ: Allianz Insurance Lanka welcomes new CEO

Allianz Taiwan maintains its leading market position in investment-linked products, benefiting from strong asset management expertise and technology capabilities as part of Allianz SE.

The insurer's strong risk-based capitalisation, supported by fee-based investment-linked products, robust fund options, and low reliance on spread gains, enhances its resilience to market fluctuations.

However, Allianz Taiwan faces challenges due to its moderate overall market presence, weak product diversification, and moderate underwriting profitability.

Follow the link s for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.